Quotes 5-day view Delayed Nasdaq
01/21/2021
01/22/2021
01/25/2021
01/26/2021
01/27/2021
Date
67.01(c)
67.74(c)
65.51(c)
62.14(c)
54.64(c)
Last
593 663
293 229
640 214
1 088 628
1 284 808
Volume
+0.22%
+1.09%
-3.29%
-5.14%
-12.07%
Change
Sales 2020
94,8 M
-
-
Net income 2020
-142 M
-
-
Net cash position 2020
509 M
-
-
P/E ratio 2020
-50,7x
Yield 2020
-
Sales 2021
160 M
-
-
Net income 2021
-164 M
-
-
Net cash position 2021
480 M
-
-
P/E ratio 2021
-46,3x
Yield 2021
-
Capitalization
7 473 M
7 473 M
-
EV / Sales 2020
73,5x
EV / Sales 2021
43,8x
Nbr of Employees
453
Free-Float
94,2%
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit.
Notations Surperformance© of Adaptive Biotechnologies Corporation
Trading Rating :
Investor Rating :
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
News in other languages on ADAPTIVE BIOTECHNOLOGIES CORPORATION
Analyst Recommendations on ADAPTIVE BIOTECHNOLOGIES CORPORATION
How Moderna executives are cashing in on COVID-19 vaccine stock speculation
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
8
Average target price
66,00 $
Last Close Price
54,64 $
Spread / Highest target
35,4%
Spread / Average Target
20,8%
Spread / Lowest Target
-15,8%
Please enable JavaScript in your browser's settings to use dynamic charts.